RTT

Stop COVID-19: Digital Health Platform

Saturday, July 11, 2020 - 12:05am

From the data collected through both tools, the health system is able to monitor those cases with symptoms and, if necessary, alerts the emergency services of the most severe cases and informs primary care centers of those with mild symptoms for their monitoring.

Key Points: 
  • From the data collected through both tools, the health system is able to monitor those cases with symptoms and, if necessary, alerts the emergency services of the most severe cases and informs primary care centers of those with mild symptoms for their monitoring.
  • The information is also used to determine the evolution of the disease at the individual level and aggregate, in order to design and implement measures and strategies..
  • The objectives of the digital tools are:
    2.
  • Be able to monitor and evaluate the symptomatology of those citizens who answer the test to validate the classification and, in case of severe symptoms, activate the emergency services.

Dynavax and Times Pharmacy Announce Partnership to Offer HEPLISAV-B® Hepatitis B Vaccine to Customers Throughout Oahu, with a Focus on People with Diabetes

Friday, July 10, 2020 - 9:01pm

Through this partnership, pharmacy customers will have access to HEPLISAV-B, the only FDA-approved two-dose hepatitis B vaccine for adults that is completed in one month.

Key Points: 
  • Through this partnership, pharmacy customers will have access to HEPLISAV-B, the only FDA-approved two-dose hepatitis B vaccine for adults that is completed in one month.
  • Preventing hepatitis B through immunization is an important part of preventive care and is critical to slowing the spread of hepatitis B, which will also help protect against new cases of liver cancer.
  • Hepatitis B is a liver infection caused by the hepatitis B virus (HBV).
  • HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

Information Update - Certain hand sanitizers may pose health risks

Friday, July 10, 2020 - 7:56pm

OTTAWA, ON, July 10, 2020 /CNW/ - Health Canada is advising Canadians that the following hand sanitizers made with industrial-grade ethanol, which is not authorized for use in hand sanitizers, may pose health risks.

Key Points: 
  • OTTAWA, ON, July 10, 2020 /CNW/ - Health Canada is advising Canadians that the following hand sanitizers made with industrial-grade ethanol, which is not authorized for use in hand sanitizers, may pose health risks.
  • For more information, including what Canadians should do, visit the online safety alert .
  • Health Canada maintains a list of hand sanitizers that may pose health risks, so that Canadians can easily identify products they may have purchased and take appropriate action.
  • Canadians are encouraged to check the list regularly for updates.

Worldwide Cystic Fibrosis Industry to 2024 - Develop In-Depth Knowledge of Competition and Markets - ResearchAndMarkets.com

Friday, July 10, 2020 - 4:48pm

This report provides comprehensive insights into the Cystic Fibrosis pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.

Key Points: 
  • This report provides comprehensive insights into the Cystic Fibrosis pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Cystic Fibrosis market size and drug sales.
  • This research covers the following: Cystic Fibrosis treatment options, Cystic Fibrosis late stage clinical trials pipeline, Cystic Fibrosis prevalence by countries, Cystic Fibrosis market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Cystic Fibrosis pipeline: Find out drugs in clinical trials for the treatment of Cystic Fibrosis by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Cystic Fibrosis drugs: Identify key drugs marketed and prescribed for Cystic Fibrosis in the US, including trade name, molecule name, and company
    Cystic Fibrosis market valuations: Find out the market size for Cystic Fibrosis drugs in 2019 by countries.

2020 Insights on the Global Idiopathic Pulmonary Fibrosis Industry - Market and Competitive Landscape - ResearchAndMarkets.com

Friday, July 10, 2020 - 4:42pm

The "Global Idiopathic Pulmonary Fibrosis Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Idiopathic Pulmonary Fibrosis Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights into the Idiopathic Pulmonary Fibrosis pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following: Idiopathic Pulmonary Fibrosis treatment options, Idiopathic Pulmonary Fibrosis late stage clinical trials pipeline, Idiopathic Pulmonary Fibrosis prevalence by countries, Idiopathic Pulmonary Fibrosis market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Idiopathic Pulmonary Fibrosis pipeline: Find out drugs in clinical trials for the treatment of Idiopathic Pulmonary Fibrosis by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Idiopathic Pulmonary Fibrosis drugs: Identify key drugs marketed and prescribed for Idiopathic Pulmonary Fibrosis in the US, including trade name, molecule name, and company
    Idiopathic Pulmonary Fibrosis drugs sales: Find out the sales value for Idiopathic Pulmonary Fibrosis drugs by countries
    Idiopathic Pulmonary Fibrosis market valuations: Find out the market size for Idiopathic Pulmonary Fibrosis drugs in 2019 by countries.

Company Profile for Reven, LLC

Friday, July 10, 2020 - 3:40pm

Reven Holdings, Inc., a Delaware corporation, through its Golden, Colorado, based operating company Reven, LLC, is a biopharmaceutical company.

Key Points: 
  • Reven Holdings, Inc., a Delaware corporation, through its Golden, Colorado, based operating company Reven, LLC, is a biopharmaceutical company.
  • Revens vision is to make a difference in the world by making its products accessible to everyone suffering the effects of vascular and metabolic related diseases.
  • Reven is committed to being the premier, research-intensive biopharmaceutical company that advances the health and well-being of people around the world.
  • Its primary product, Rejuveinix (RJX), targets patients suffering from COVID-19, sepsis, vascular and metabolic related diseases as well as specific patient populations suffering PAD and other cardiovascular related medical conditions.

AGENT Study Update With Regards to COVID-19

Friday, July 10, 2020 - 2:25pm

As hospitals, regions and countries have updated their guidelines, Isofol has adapted accordingly to be fully compliant with the new procedures.

Key Points: 
  • As hospitals, regions and countries have updated their guidelines, Isofol has adapted accordingly to be fully compliant with the new procedures.
  • In order to ensure continuity of the ongoing AGENT study in a safe and responsible manner, the company has implemented a number of proactive measures and is working closely with local health authorities on an ongoing basis.
  • To date, we are nearing the 330 patients of the total study target of required 440 patients.
  • Over 90 sites in the USA, Canada, Europe, Australia and Japan are currently recruiting patients in the AGENT study who will receive first line treatment for metastatic colorectal cancer (mCRC).

Global Retinal Surgery Devices Market by Product Type, Application and Geography - Forecast to 2025 - ResearchAndMarkets.com

Friday, July 10, 2020 - 2:03pm

The "Retinal Surgery Devices Market - Growth, Trends, and Forecast (2020-2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Retinal Surgery Devices Market - Growth, Trends, and Forecast (2020-2025)" report has been added to ResearchAndMarkets.com's offering.
  • The global retinal surgery devices market is expected to register a CAGR of 7.9% during the forecast period.
  • Growing instances of retinal disorders in geriatric population, eye injuries and rising prevalence of diabetic retinopathy are the key driving factors in the retinal surgery devices market.
  • Increasing prevalence of diabetes, retinal disorders, eye injuries and rising geriatric population are the key driving factors in the retinal surgery devices market.

DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut in The Journal of Allergy and Clinical Immunology

Friday, July 10, 2020 - 2:00pm

DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that The Journal of Allergy and Clinical Immunology (JACI) has published results from its three-year, open-label extension of the Phase III PEPITES study (PEOPLE).

Key Points: 
  • DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that The Journal of Allergy and Clinical Immunology (JACI) has published results from its three-year, open-label extension of the Phase III PEPITES study (PEOPLE).
  • If approved, DBV712 would be the first once-daily, non-invasive epicutaneous treatment option for children living with peanut allergy.
  • In my clinical practice, I see many patients and their families who struggle with the burden of peanut allergy and the fear of accidental exposure.
  • Sustained unresponsiveness following long term Epicutaneous Immunotherapy (EPIT) with VIASKIN peanut: Results of the OLFUS VIPES PHASE IIb Study.

Global Menopause Market (2020 to 2024) - Develop In-depth Knowledge of Competition and Markets - ResearchAndMarkets.com

Friday, July 10, 2020 - 1:03pm

The "Global Menopause Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Menopause Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights into the Menopause pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Menopause market size and drug sales.
  • This research covers the following: Menopause treatment options, Menopause late stage clinical trials pipeline, Menopause prevalence by countries, Menopause market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.